Barclays capital-at-risk pharma note pays 9.75% in the US

Coupons and capital risk


Barclays in the US has issued a 12-month structured product tied to the performance of the common stock of Valeant Pharmaceuticals International. The note will pay a fixed monthly coupon even if the price of the underlying falls below the barrier level during the monitoring period. Capital is at risk if the price of the underlying stock falls below the protection level at the close of any business day and stays below the initial level on the final valuation date.

This product is a reverse conver

To continue reading...